46,XY DSD with Female or Ambiguous External Genitalia at Birth due to Androgen Insensitivity Syndrome, 5α-Reductase-2 Deficiency, or 17β-Hydroxysteroid Dehydrogenase Deficiency: A Review of Quality of Life Outcomes by Amy B. Wisniewski & Tom Mazur
Hindawi Publishing Corporation
International Journal of Pediatric Endocrinology
Volume 2009, Article ID 567430, 7 pages
doi:10.1155/2009/567430
Review Article
46,XY DSD with Female or Ambiguous External Genitalia at Birth
due to Androgen Insensitivity Syndrome, 5α-Reductase-2
Deficiency, or 17β-Hydroxysteroid Dehydrogenase Deficiency:
A Review of Quality of Life Outcomes
Amy B. Wisniewski1 and Tom Mazur2
1 Section of Pediatric Diabetes and Endocrinology, Department of Pediatrics, University of Oklahoma Health Sciences Center,
940 NE 13th Street, Room 2B2426, Oklahoma City, OK 73117, USA
2Department of Pediatrics, State University of New York, Buﬀalo, NY 14222, USA
Correspondence should be addressed to Amy B. Wisniewski, amy-wisniewski@ouhsc.edu
Received 3 June 2009; Accepted 29 July 2009
Recommended by Peter Lee
Disorders of sex development refer to a collection of congenital conditions in which atypical development of chromosomal,
gonadal, or anatomic sex occurs. Studies of 46,XYDSD have focused largely on gender identity, gender role, and sexual orientation.
Few studies have focused on other domains, such as physical and mental health, that may contribute to a person’s quality of
life. The current review focuses on information published since 1955 pertaining to psychological well-being, cognition, general
health, fertility, and sexual function in people aﬀected by androgen insensitivity syndromes, 5-α reductase-2 deficiency, or 17β-
hydroxysteroid dehydrogenase-3 deficiency—reared male or female. The complete form of androgen insensitivity syndrome has
been the focus of the largest number of investigations in domains other than gender. Despite this, all of the conditions included
in the current review are under-studied. Realms identified for further study include psychological well-being, cognitive abilities,
general health, fertility, and sexual function. Such investigations would not only improve the quality of life for those aﬀected by
DSD but may also provide information for improving physical and mental health in the general population.
Copyright © 2009 A. B. Wisniewski and T. Mazur. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. Introduction
Disorders of sex development (DSD) refer to a collection
of congenital conditions in which atypical development of
sex occurs at one or more levels (chromosomal, gonadal,
anatomic). Genetic males with DSD (i.e., 46,XY DSD) can
present with an external genital phenotype that is female,
ambiguous, or male including a micropenis (stretched penile
length <2.5 SD for age). Studies of 46,XY DSD have focused
largely on aspects of gender development such as satisfaction
with gender of rearing, sexual orientation, gender identity,
and gender role (GI/R) [1]. Very few studies have reported
on additional aspects of physical or mental health despite
the fact that patients and families often inquire about such
topics. Furthermore, few studies have addressed the question
of if, or how, a DSD diagnosis and related treatment impact
quality of life (QoL) for aﬀected individuals. For the purpose
of this review, QoL can be operationally defined as the
amount of enjoyment a person experiences in the physical,
psychological, social, and spiritual dimensions of their life
[2].
Although much remains to be learned concerning psy-
chosexual development as it relates to DSD, the purpose
of this paper is to review what is known about aspects
of physical and mental health that contribute to overall
QoL beyond GI/R and sexual orientation. Topics reviewed
include QoL and psychological well-being, cognition, gen-
eral health, fertility, and sexual function. Additionally, the
focus of this review is on individuals aﬀected by 46,XY
DSD due to androgen insensitivity syndromes (AIS), 5-
α reductase-2 deficiency (5α-RD-2), or 17β-hydroxysteroid
dehydrogenase-3 deficiency (17β-HSD-3)—reared male or
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female. These conditions were chosen because while much
has been written about gender development in aﬀected
individuals, less emphasis has been placed on other outcomes
that may contribute to QoL such as genital surgery or
hormone therapy to induce and maintain pubertal devel-
opment. Congenital micropenis was not included in the
current review because too little information exists on
outcomes aside from gender development in this DSD for
meaningful interpretation of the data. Data on individuals
with micropenis is further confused by the incorrect practice
of some authors of describing individuals with a small
phallus including hypospadias as having a micropenis.
2. Methods
A search of the databases Medline and Psyc INFO was
performed using the terms disorders of sex development,
DSD, intersex, hermaphrodite, male pseudohermaphrodite,
ambiguous genitalia, androgen insensitivity, 5-α reductase-
2 deficiency, and 17β-hydroxysteroid dehydrogenase-3 defi-
ciency. Peer-reviewed articles published in English since 1955
were considered if they referred to adults with DSD grouped
and analyzed according to the above-mentioned etiologies.
The year 1955 was chosen because this was when JohnMoney
started to publish extensively on DSD in peer-reviewed
scientific journals [3, 4].
To be considered for inclusion in the current review,
articles must report on mental or physical health outcomes
other than, or in addition to, GI/R and sexual orientation.
Articles were excluded if they provided outcome information
about GI/R or sexual orientation only, or when data from
study participants could not be attributed to one of the
specific DSD diagnoses referred to earlier. A total of 35
articles were located and reviewed according to these criteria.
3. Androgen Insensitivity Syndromes (AISs)
AISs in either the complete (CAIS) or partial (PAIS) form
represent a relatively common presentation of 46,XY DSD
[5–7]. CAIS and PAIS result in complete or partial end
organ insensitivity to androgens, respectively. The majority
of mutations of the human androgen receptor gene are
base substitutions, although base and gene deletions, base
insertions, and premature terminations occur.While it is well
established that androgens bind to intracellular androgen
receptors to alter gene expression in target tissues, evidence
for nongenomic actions of androgens is accumulating [8].
The degree of androgen insensitivity of target tissues is
usually inferred by the extent of under-masculinization of the
external genitalia at birth coupled with the degree of under-
virilization at puberty.
The clinical presentation of CAIS in adulthood is typi-
cally that of a tall woman with a female distribution of adi-
pose tissue, female breasts and external genital development,
and little or no sexual hair. Infants can present with testes
that descend into the inguinal canals or labia, and adolescents
can present with absent menses and sexual hair in conjunc-
tion with normal breast development. Due to the female
external genital phenotype associated with CAIS, aﬀected
individuals are always assigned and reared as girls despite
their possession of a 46,XY chromosomal complement and
testes. Individuals with PAIS typically present as newborns
with varying degrees of genital ambiguity. Thus, male or
female sex of rearing occurs, depending on the degree of
under-masculinization of the genitalia.
3.1. Health-Related Quality of Life, Psychological Well-Being,
and Aﬀective Disorders in CAIS. While psychosexual evalu-
ations of girls and women aﬀected by CAIS unequivocally
reveal female GI/R [9–11], outcomes of other aspects of
mental health vary greatly across studies. For example, psy-
chological distress as assessed by the Brief Symptom Inventory
(BSI), self-harming behavior, and suicidal tendencies are
prevalent in some samples of women with CAIS recruited
from physicians or support groups [12–14]. In a study of
women with CAIS recruited from subspecialty clinics at a
University Hospital, participants aﬀected by CAIS reported
better QoL scores and fewer depressive symptoms than
women with other types of DSD or unaﬀected control
women when assessed with the Danish version of theQuality
of Life-Assessment of Growth Hormone Deficiency in Adults
(QoL-AGHDA) questionnaire [15]. In yet another study
of women with CAIS recruited from both a clinic sample
and a support group, aﬀected individuals did not diﬀer
from controls on measures of self-esteem, assessed by the
Self-Esteem Scale, or psychological well-being, measured
by responses to the Psychological General Well-Being Scale
(PGWBS) [12]. While it is surprising that some studies
of women with CAIS report equal or better QoL than
unaﬀected women, this may be due to small sample sizes and
participation bias. Additional QoL studies including larger
sample sizes and greater participant diversity are needed in
this population to better understand the impact of having
a 46,XY chromosomal complement and being born with
testes on overall psychological well-being in this group of
women. Recently, the German Network of Disorders of
Sex Development published clinical evaluation data on 439
individuals with DSD [16]. QoL information from this
study sample will prove extremely valuable when published.
Furthermore, a study that assesses potential diﬀerences in
long-term QoL among women with CAIS whose testes were
removed during infancy, compared to those who consented
to gonadectomy later in their development, would provide
very useful information for optimizing medical and surgical
treatment for this group.
3.2. Cognition in CAIS. Mice with androgen receptor gene
mutations (testicular feminization mutant or tfm) exhibit a
more pronounced impairment on spatial recognition and
memory retention tasks when considered in conjunction
with the epsilon4 allele of the apolipoprotein E gene (apoE4)
[17]. This subclass of apolipoprotein plays an important role
in cholesterol metabolism and is associated with Alzheimer’s
disease, impaired cognition, and reduced neurite growth
[18]. The implication is that androgen insensitivity may
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impact cognition in women aﬀected by AIS who also express
the epsilon 4 allele of the APOE gene.
Only two studies of cognitive performance in girls
and women aﬀected by CAIS exist in the peer-reviewed
literature. The first employed standardized, age-appropriate
intelligence testing for participants ranging in age from 5 to
28 years and observed normal scores for all of the girls and
women who participated [19]. A second intelligence assess-
ment was performed in women with CAIS and revealed no
group diﬀerences in overall IQ between CAIS participants,
unaﬀectedmen, and unaﬀected women [20]. However, unaf-
fected women and those with CAIS performed worse than
men on visuospatial components of the IQ measure. Taken
together, these data reveal that girls and women with CAIS
exhibit similar IQ scores and cognitive performance patterns
as unaﬀected women who possess a 46,XX chromosomal
complement and end organ responsiveness to androgens.
Whether or not cognitive diﬀerences would be detected on
measures of spatial recognition and memory for women
aﬀected by CAIS when apoE4 is considered is not known
at this time. Future studies should consider the potential
interaction of end organ unresponsiveness to androgens
with apoE4 in this population. Additionally, more refined
neuropsychological testing, regardless of apoE4 status, might
reveal important cognitive diﬀerences in girls and women
aﬀected by this type of DSD.
3.3. General Health in CAIS. Few long-term outcome studies
of general health have been conducted in women with CAIS.
Obesity is commonly reported, however, at rates that mimic
the general population of women [10, 21]. Decreased bone
mineral densities in the lumbar spine and hip regions occur
both prior to gonadectomy in women with CAIS as well as
in gonadectomized women receiving daily estrogen therapy
[10, 21, 22]. These data suggest that women aﬀected by CAIS
are at an increased risk for osteoporosis despite exposure to
endogenous or exogenous estrogen. Whether women with
CAIS require higher doses of estrogen than their unaﬀected
counterparts to protect their bones, or whether androgens
play a direct role in bone health for this group, is unknown
at this time.
Concerning cancer occurrence and risk, both germ cell
tumor formation and risk factors for developing prostate
cancer have been investigated in women with CAIS. Prepu-
bertal girls with CAIS are considered to be at low risk (≈2%)
for germ cell tumor formation, as determined by review of
55 patients [23]. However, a seminoma has been reported in
a 14-year-old with CAIS [24], and a malignant teratoma has
been reported in a second aﬀected child (also 14-years-old)
[25]. In general, the risk for developing testicular tumors—
including sertoli cell tumors, seminomas, and leydig cell
tumors—is thought to increase with age in aﬀected women
[26, 27]. Additionally, women with CAIS appear to be at low
risk for developing prostate cancer as determined by prostate
specific antigen (PSA) testing and digital rectal exam, despite
their possession of some prostate tissue [28]. No studies were
located that investigated other types of cancer occurrence or
risk in women with CAIS.
3.4. Fertility and Sexual Function in CAIS. As women with
CAIS possess neither ovaries nor a uterus, fertility is not
possible in this group at the present time. While vaginal
lengthening is needed for penile penetration in some women
with CAIS [29, 30], others have a normal vaginal length
and report satisfactory intercourse despite never having
received dilatation or surgery [10, 31]. Three studies of
orgasmic function report that women with CAIS can reach
sexual climax [10, 32, 33], indicating that androgens are not
necessary for this aspect of sexuality in this group. Low libido,
or hyposexual function, is reported by some women with
CAIS [33, 34]. Interestingly, even when women report sexual
dysfunction, they also report sexual satisfaction at levels that
equal unaﬀected women [34]. Perhaps hyposexual function
associated with CAIS is secondary to vaginal hypoplasia, the
need for androgens to support libido (but not orgasm), or
sexual avoidance by women who feel stigmatized by their
medical condition. Further research that includes unaﬀected
women as control subjects is needed to understand the
extent, and underlying causes, of hyposexual function in
women aﬀected by this 46,XY DSD. Additionally, future
studies would benefit from considering the impact of the
type and timing of vaginoplasty on sexual satisfaction—an
important component of QoL.
3.5. Health-Related Quality of Life, Psychological Well-Being,
and Aﬀective Disorders in PAIS. Self-reported psychologi-
cal distress as determined by responses to the BSI, self-
harming behavior, suicidal tendencies, and suicidal attempts
is observed in people aﬀected by PAIS—whether reared male
or female [12–14]. In a long-term followup study of adults
with PAIS, psychological counseling for problems such as
diﬃculty with family members, depression, and substance
abuse was commonly reported during interviews—once
again regardless of male or female rearing [35]. However,
some studies of men and women aﬀected by PAIS fail to
observe significant problems with mental health [36, 37].
Furthermore, QoL as determined by responses to the SF-36
Health Survey exceeded normative data in one case series of
3 women aﬀected by PAIS [38]. While it is clear that some
individuals with PAIS experience mental health obstacles,
both the extent and type of these obstacles in this patient
population remain to be elucidated. The potential impact
of clinical decisions such as the type and timing of genital
surgeries on QoL in aﬀected people, regardless of their
gender assignment, is important information that is missing
from our knowledge base at this time.
3.6. General Health and Cognition in PAIS. Based on studies
of 24 patients, people with PAIS are thought to be at high
risk (≈50%) for developing germ cell tumors if the testes are
not located in the scrotum. For this group, gonadectomy is
recommended at the time of diagnosis [23]. 46,XY women
aﬀected by PAIS do not appear to be at risk for developing
prostate cancer, despite their possession of prostate tissue, as
determined by PSA levels and digital rectal exam. Presumably
this is due to the fact that these women are gonadectomized,
and thus protected from androgenic actions on the prostate.
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In contrast, men with PAIS have PSA levels comparable to
unaﬀected men matched for age and race [28]. Therefore,
when individuals with PAIS are reared male, screening for
prostate disease is recommended in a manner that is similar
to the general male population. No other published reports
on general health outcome in 46,XY individuals with PAIS,
reared male or female, were located. Additionally, no studies
on cognition in this group were found.
3.7. Fertility and Sexual Function in PAIS. At the present time
fertility is challenging, but not impossible, for individuals
with PAIS raised male [39, 40]. In contrast, fertility is
not possible for individuals raised female. A study of 15
adults reared male found that none had ever engaged in
penile-vaginal intercourse and all experienced severe sexual
dysfunction [41]. In a second study of 21 men and 18
women with 46,XY DSD due to PAIS, most had participated
in sexual relationships. Dissatisfaction with sexual function
was common but not universal, and this dissatisfaction
was similar for those reared male or female [35]. Smaller
investigations of sexual function in women with PAIS reveal
that, for those who participated in sexual relations with a
partner, those experiences were rated as both satisfactory
[37] and unsatisfactory [29, 37]. The great variability in
outcome measures across studies indicates the need to study
larger sample sizes [16] as well as employ standardized,
validated measures of sexual function when examining men
and women with PAIS.
4. 5α-Reductase-2 Deficiency
5α-reductase-2 (5α-RD-2) deficiency can result in female
external genitalia (with a normal sized or enlarged clitoris)
and male internal sex ducts in people with a 46,XY chromo-
somal complement. This occurs because the enzyme 5α-RD-
2 is needed to convert testosterone to dihydrotestosterone
(DHT). DHT has a greater aﬃnity for the androgen receptor
than testosterone and is required to masculinize the external
genitalia, but not the internal male sex ducts, during fetal
development. Testosterone alone is suﬃcient to support
somatic virilization postnatally [42, 43].
4.1. Health-Related Quality of Life, Psychological Well-Being,
and General Health in 5α-RD-2 Deficiency. Clinical distress,
determined by responses to the BSI and suicidal ideation, is
observed in 46,XY women aﬀected by 5α-RD-2 deficiency,
although studies of larger sample sizes are needed to deter-
mine the generalizability of this finding [14]. Whether this
distress is due to female assignment, feminizing surgeries, or
both is unknown at this time. A bone health investigation
of aﬀected adults (none of whom had been gonadectomized
nor given exogenous hormone replacement) revealed that
bone mineral density did not diﬀer from unaﬀected men
[22]. A second bone density study concluded that DHT is
not needed to maintain normal bone health [44]. No other
studies on general health outcomes were located for review
for this particular group of DSD. Of particular concern is
the lack of knowledge pertaining to germ cell tumor [23]
or prostate cancer [28] risk for this group. Additionally, no
studies of cognitive performance were located.
4.2. Fertility and Sexual Function in 5α-RD-2 Deficiency.
Both sperm production and paternity have been docu-
mented in men aﬀected by 5α-RD-2 deficiency [43, 45–48].
High-dose androgen therapy improves virilization, erectile
response and ejaculatory volume in individuals reared male
[45]. For those who identify as women, sexual activity is
reported to be satisfactory following vaginal dilatation [44].
Similar to AIS, it is not clear how sexual function in people




17β-HSD-3 deficiency results in impaired testicular conver-
sion of androstenedione to testosterone [49]. The clinical
presentation of 17β-HSD-3 deficiency can be confused with
CAIS as aﬀected individuals often present with female
external genitalia prior to puberty [50, 51]. If the testes
remain in situ, virilization at puberty occurs in amanner that
is similar to what is observed in 5α-RD-2 deficiency [50, 52].
5.1. Health-Related Quality of Life, Psychological Well-Being,
and General Health in 17β-HSD-3 Deficiency. Clinical dis-
tress as determined by the BSI and suicidal ideation is
observed in 46,XY women aﬀected by 17β-HSD-3 deficiency,
but interpretation of these data is limited by the small sample
size studied [14]. Once again, how gender assignment and
the medical and surgical treatment that accompanies such
assignment impact QoL for this group is unknown. Germ cell
tumor risk is estimated to be intermediate (≈28%) [23, 50].
No other studies of general health or cognition conducted in
this category of 46,XY DSD were located for review.
5.2. Sexual Function and Fertility in 17β-HSD-3 Deficiency.
Case reports of 46,XY women with 17β-HSD-3 deficiency
indicate satisfactory sexual function [44, 53], but available
information is too incomplete to draw conclusions with
confidence. Case reports of aﬀected individuals living as men
also indicate satisfactory sexual function [50, 53], although
dissatisfaction attributed to having a small phallus appears
in the literature [51].
6. Summary and Conclusions
Of the 35 studies reviewed that included outcomes informa-
tion apart from gender, 24 included information about CAIS,
9 about PAIS, 11 about 5α-RD-2 deficiency, and 5 about
17β-HSD-3 deficiency. Possibly, greater emphasis has been
placed on studying CAIS apart from gender because female
rearing in this particular DSD is undisputed. In contrast,
male or female rearing occurs in people aﬀected by PAIS, 5α-
RD-2, and 17β-HSD-3 deficiencies. Perhaps GI/R and sexual
orientation have been the focus of studies in these conditions
in response to the clinical challenges of assigning gender in
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aﬀected individuals. Finally, because CAIS has an animal
model (tfm) associated with it, this condition may lend itself
more easily to scientific investigation.
Results from studies of psychological well-being in the
specific 46,XY DSD categories considered here vary greatly
across investigations. This is likely due to the fact that these
include only a handful of participants, interviewed only
once, in no particular relation to developmental stage or
medical/surgical event. Future studies should include larger
samples and take into account developmental stages as well as
the potential impact of corresponding medical and surgical
procedures associated with these stages [16]. Additionally,
for those who have access to mental health services, it is
critical to determine the eﬀectiveness of these services on
psychological well-being within specific categories of DSD.
No systematic studies of IQ or cognition have been
conducted in people aﬀected by 46,XY DSD due PAIS or
androgen biosynthetic defects due to 5α-RD-2 or 17β-HSD-
3 deficiencies. Unlike tfm rodent models, it is unknown if
women with CAIS are more likely to develop spatial memory
problems if they also express the epsilon 4 allele of the APOE
gene. As individuals with 46,XY DSD are generally expected
to live a full lifespan, a more complete understanding of
the potential for their DSD to impact neuropsychological
development, particularly later in development, is needed.
General health outcome studies in people aﬀected by
AIS, 5α-RD-2 deficiency, and 17β-HSD-3 deficiency are few
and have been limited to gonadal tumors, and bone and
prostate health. Further health outcome studies, particularly
in conditions that exhibit clear sex diﬀerences or influences
of sex steroid action, are needed. For example, whether or
not possession of a Y chromosome places 46,XY women at
risk for developing a male-typical presentation and course
of cardiovascular disease, independent of androgen action,
is not known. Alternatively, it is currently unknown if
under-masculinized genetic males have an elevated risk
for developing female-typical medical conditions such as
autoimmune diseases or depression. As our understanding
of DSD broadens to include physical and mental health
outcomes apart from gender development, it is anticipated
that QoL will improve for aﬀected individuals.
Fertility and sexual function can be important compo-
nents to living a fulfilled life and maintaining relationships;
yet we know very little about such topics. We do know from
patient populations aﬀected by conditions other than DSD
that infertility [54] sexual dysfunction [55] and surgeries
to the reproductive organs [56] negatively impact health-
related QoL. Such information, as it pertains specifically
to DSD, is crucial in optimizing treatment and supporting
aﬀected individuals.
Knowledge about the physical and mental health out-
comes in DSD throughout the life cycle is important for
improving or maintaining health in aﬀected individuals and
the population overall. For example, the few studies of
bone health that have been conducted in AIS and 5α-RD-2
deficiency imply that testosterone, but not DHT, is necessary
for optimizing bone density. Such information may be useful
for developing treatments for conditions such as osteopenia
and osteoporosis.
It is important to focus on QoL factors for persons
with a DSD diagnosis because parents ask questions such
as How will my child perform in school? Will my child
establish friendships? Will my child have a career? Will my
child fall in love? Parents also want to know how their
children will feel about their DSD diagnosis. In short, parents
want information about their aﬀected child’s future QoL.
Only through systematic investigation of such questions
will answers be obtained, and appropriate interventions
developed.
We could find no data pertaining to individual adjust-
ment to the categories of DSD discussed in the current
review. Additionally, very little is known about how family
members respond to a child’s diagnosis of DSD. While we
know that parents of children aﬀected by CAIS or PAIS
report feelings of shock, grief, anger, and shame when they
learn of their child’s condition [57], more studies of parents
are needed as their attitudes surely exert a significant impact
on subsequent child health and well-being [58]. Finally,
the definition for QoL presented earlier includes social and
spiritual components—neither of which were investigated
systematically in any of the papers reviewed.
In conditions in which GI/R does not always develop in
concordance with sex of rearing—such as PAIS, 5α-RD-2
deficiency, and 17β-HSD-3 deficiency—a better understand-
ing of factors that influence QoL may help to explain the
developmental trajectory of GI/R in people for whom GI/R
development does not match their initial gender assignment
[11]. We still have a long way to go in understanding why
some people with these conditions change gender while
others do not. Importantly, approximately a third of people
withDSD other than AIS, 5α-RD-2 deficiency, or 17β-HSD-3
deficiency are born with malformations that likely aﬀect QoL
[59]. Future studies must consider those individuals as well.
This review has attempted to show that we also have a long
way to go before we have a full appreciation of the mental,
physical, social, and spiritual domains that contribute to QoL
of people aﬀected by 46,XY DSD who are born with either
female or ambiguous external genitalia.
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